The stock is listed on the Nasdaq Global Select Market

Davis Polk advised the representatives of the several underwriters in connection with the $200 million public offering by Solid Biosciences Inc. of 35,739,810 SEC-registered shares of common stock and SEC-registered pre-funded warrants to purchase 13,888,340 shares of common stock. The common stock is listed on the Nasdaq Global Select Market under the symbol “SLDB.”

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Joyce Kim. Partner David R. Bauer and associates Adrian Rabin and Elizabeth Pott provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post